OBJECTIVETo explore whether there is difference in arsenicals-induced DNA damage of human lymphocyte.

METHODSLymphocyte were sterilely collected from healthy donor and exposed to sodium arsenite (AsIII), sodium arsenate(AsV) and methyl sodium arsenate(MAsv) at 1,5,10,20 and 50 mumol/L. After incubation of 24 hours, cells were collected by centrifugation and DNA damage was detected by single cell gel electrophoresis (SCGE).

RESULTSThe comet frequency distribution of all groups except 1 mumol/L group of MAsV were significantly different from that of control. The comet length of all groups except 1 mumol/L group of AsV and 1.5 mumol/L groups of MAsV were significantly higher than that of control. There were correlations between the doses of arsenicals and the ratios of comet cell or length of comet(rAsIII = 0.8134, rAsV = 0.8734, rMAsV = 0.8994).

CONCLUSIONDNA damage in human lymphocyte were induced by all the three arsenicals. A dose-effect relationship was observed between exposure doses of the same arsenical and DNA damage. With different arsenicals but the same exposure dose, the DNA damage level was as follow: AsIII > AsV > MAsV.

Arsenates ; toxicity ; Arsenites ; toxicity ; Comet Assay ; DNA Damage ; Dose-Response Relationship, Drug ; Humans ; Lymphocytes ; drug effects ; ultrastructure

Animals ; Arsenates ; toxicity ; Female ; Kidney ; drug effects ; Lipid Metabolism ; drug effects ; Liver ; drug effects ; Oxidative Stress ; drug effects ; Rats, Wistar

OBJECTIVETo study the combined effect of fluoride and arsenate on the expression of SD rat osteoblastic osteoclast differentiation factor (ODF) mRNA and osteoprotegerin (OPG) mRNA.

METHODSOsteoblasts were obtained by enzymatic isolation from newborn SD rats. A factorial experiment was performed. Osteoblasts were exposed to NaF (0.5 mmolF/L, 4 molF/L) and Na3AsH2 (12.5 micromolAs/L and 200 micromolAs/L) separately or F plus As and cultured for 48 h. The gene expression of osteoblastic ODF and OPG was observed by RT-PCR.

RESULTSThe expression of ODF mRNA increased in F0.5, F4 groups compared with control group and two groups of F0.5As200, F4As200 compared with As200 group, and decreased significantly in groups of F4Asl2.5, F0.5As200, and F4AS200. The expression of OPG mRNA decreased in groups of F4, As200, F4As12.5, F0.5AS200, and F4AS200.

CONCLUSIONThe joint effect of fluoride and arsenate on the gene expression of ODF is antagonistic, while the combined effect on the gene expression of OPG is synergistic. F4, F4As12.5, and F0.5As200 promote bone resorption of rat osteoclasts, whereas F0.5As12.5 inhibits osteolytic effect of rat osteoclasts.

Animals ; Animals, Newborn ; Arsenates ; pharmacology ; Bone and Bones ; drug effects ; Cariostatic Agents ; pharmacology ; Fluorides ; pharmacology ; Gene Expression ; drug effects ; Hazardous Substances ; pharmacology ; Osteoblasts ; cytology ; drug effects ; Osteoprotegerin ; biosynthesis ; genetics ; RANK Ligand ; biosynthesis ; genetics ; Rats

The paper is to report the preparation of realgar bioleaching solution (RBS) by bacteria and the comparison of pharmacokinetics of RBS and H3AsO3 (ATO), and the study of its possible change of absorption and distribution of soluble arsenic in rat. The experiment was carried out on Wistar rats given peritoneal injection of RBS at a dose of 0.3 mg x kg(-1) (soluble arsenic content, 0.3 mg x kg(-1)), and rats given ATO at the dose of 0.3 mg x kg(-1) (soluble arsenic content, 0.3 mg x kg(-1)). The arsenic concentrations in many tissues including heart, liver, spleen, lung, renal and brain were determined. The changes of pharmacokinetic parameters and arsenic distribution in different tissues were detected and compared in these two groups of rats. The pharmacokinetic parameters of RBS and ATO are very similar. There is very few distribution of arsenic in the tissues in RBS group, compared with the ATO group. There is significant difference in the content of arsenic between two groups statistically (P < 0.01). It is feasible that we select the bacteria bioleaching solution as a candidate drug, which may be employed for primary change of arsenic compounds including dissolved inorganic arsenic and organic arsenic, in order to improve bioavailability and decrease the amount of arsenic accumulation in animal tissues. In addition, there is significant difference in the change of arsenic compounds between two groups. It can be concluded that, the investigation on application of microbial technology may provide a basis for exploratory research of realgar.
Animals ; Area Under Curve ; Arsenates ; pharmacokinetics ; Arsenic ; metabolism ; Arsenicals ; administration & dosage ; pharmacokinetics ; Bacteria ; metabolism ; Electrophoresis, Capillary ; methods ; Female ; Injections, Intraperitoneal ; Male ; Rats ; Rats, Wistar ; Solutions ; Sulfides ; administration & dosage ; pharmacokinetics ; Therapeutic Equivalency ; Tissue Distribution